Akeso Announces Approval for Phase II Trials of Innovative Bispecific Antibody Targeting Respiratory and Autoimmune Diseases Akeso, Inc. has received approval for Phase II clinical trials for its bispecific antibody, AK139, which targets respiratory and autoimmune diseases, marking a significant advancement in treatment options.

Akeso Announces Approval for Phase II Trials of Innovative Bispecific Antibody Targeting Respiratory and Autoimmune Diseases #China #Hong_Kong #Akeso #bispecific_antibody #AK139

Akeso's AK139: A Revolutionary Bispecific Antibody for Respiratory and Skin Disorders Akeso has received IND acceptance for AK139, a bispecific antibody aiming to tackle respiratory and skin diseases by targeting IL-4Rα and ST2 pathways.

Akeso's AK139: A Revolutionary Bispecific Antibody for Respiratory and Skin Disorders #Hong_Kong #Akeso #bispecific_antibody #AK139